Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple MyelomaJin Jie, Hong Ma, Min Yang et al.|Blood|2019Cited by 40
Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple MyelomaSiguo Hao, Hong Ma, Jie Jin et al.|Blood|2020Cited by 36